Cargando…

Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia

Background. Metformin is a widely accepted first-line pharmacotherapy for patients with type 2 diabetes mellitus (T2DM). Treatment of T2DM with glibenclamide, saxagliptin, or one of the other second-line treatment agents is recommended when the first-line treatment (metformin) cannot control the dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bekele, Mengistu, Norheim, Ole Frithjof, Hailu, Alemayehu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111283/ https://www.ncbi.nlm.nih.gov/pubmed/34104781 http://dx.doi.org/10.1177/23814683211005771

Ejemplares similares

Measuring progress towards universal health coverage: national and subnational analysis in Ethiopia
por: Eregata, Getachew Teshome, et al.
Publicado: (2019)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

A cost-effectiveness analysis of maternal and neonatal health interventions in Ethiopia
por: Memirie, Solomon Tessema, et al.
Publicado: (2019)

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Generalised cost-effectiveness analysis of 159 health interventions for the Ethiopian essential health service package
por: Eregata, Getachew Teshome, et al.
Publicado: (2021)

Equity in public health spending in Ethiopia: a benefit incidence analysis
por: Hailu, Alemayehu, et al.
Publicado: (2021)

Priority setting: the importance of incorporating opportunity costs
por: Norheim, Ole Frithjof
Publicado: (2012)

Glibenclamide: A second wind for refractory hyperkalemia
por: Senthilkumaran, Subramanian, et al.
Publicado: (2014)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin
por: Doggrell, Sheila A
Publicado: (2014)

Cost of childhood cancer treatment in Ethiopia
por: Mirutse, Mizan Kiros, et al.
Publicado: (2023)

Assessing the burden of medical impoverishment by cause: a systematic breakdown by disease in Ethiopia
por: Verguet, Stéphane, et al.
Publicado: (2016)

Understanding Inequalities in Child Health in Ethiopia: Health Achievements Are Improving in the Period 2000–2011
por: Skaftun, Eirin Krüger, et al.
Publicado: (2014)

Health inequalities in Ethiopia: modeling inequalities in length of life within and between population groups
por: Tranvåg, Eirik Joakim, et al.
Publicado: (2013)

Country contextualisation of cost-effectiveness studies: lessons from Ethiopia
por: Johansson, Kjell Arne, et al.
Publicado: (2019)

Cost-effectiveness of running a paediatric oncology unit in Ethiopia
por: Kiros, Mizan, et al.
Publicado: (2023)

Is cost-effectiveness analysis preferred to severity of disease as the main guiding principle in priority setting in resource poor settings? The case of Uganda
por: Kapiriri, Lydia, et al.
Publicado: (2004)

Maternal and Neonatal Mortality in South-West Ethiopia: Estimates and Socio-Economic Inequality
por: Yaya, Yaliso, et al.
Publicado: (2014)

Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2019)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis
por: Tolla, Mieraf Taddesse, et al.
Publicado: (2016)

Kombiglyze (metformin and saxagliptin)‐induced hepatotoxicity in a patient with non‐alcoholic fatty liver disease
por: Thalha, Abdul Malik, et al.
Publicado: (2018)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Out-of-pocket expenditures for prevention and treatment of cardiovascular disease in general and specialised cardiac hospitals in Addis Ababa, Ethiopia: a cross-sectional cohort study
por: Tolla, Mieraf Taddesse, et al.
Publicado: (2017)

Glibenclamide or Metformin Combined with Honey Improves Glycemic Control in Streptozotocin-Induced Diabetic Rats
por: Erejuwa, Omotayo Owomofoyon, et al.
Publicado: (2011)

Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis
por: Balsells, Montserrat, et al.
Publicado: (2015)

Comparative Study of the Antioxidant Effects of Metformin, Glibenclamide, and Repaglinide in Alloxan-Induced Diabetic Rats
por: Chukwunonso Obi, Bonaventure, et al.
Publicado: (2016)

Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets
por: Belayneh, Anteneh, et al.
Publicado: (2020)

Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension
por: Cosenso-Martin, Luciana Neves, et al.
Publicado: (2015)

Towards universal health coverage for reproductive health services in Ethiopia: two policy recommendations
por: Onarheim, Kristine Husøy, et al.
Publicado: (2015)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Antioxidant Protective Effect of Glibenclamide and Metformin in Combination with Honey in Pancreas of Streptozotocin-Induced Diabetic Rats
por: Erejuwa, Omotayo Owomofoyon, et al.
Publicado: (2010)

Comparison of Antioxidant Effects of Honey, Glibenclamide, Metformin, and Their Combinations in the Kidneys of Streptozotocin-Induced Diabetic Rats
por: Erejuwa, Omotayo Owomofoyon, et al.
Publicado: (2011)

Glibenclamide, ATP and metformin increases the expression of human bile salt export pump ABCB11
por: Vats, Nisha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rcfamarh54mnt5di031ddl9mfs